Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EB-1020 in Adults With ADHD
NCT06931080Phase 3Recruiting
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of centanafadine in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Adult ADHD Investigator Symptom Rating Scale at 6 weeks. Started Apr 2025; status: recruiting.
02
Drugs
centanafadine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT06931080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06931080.